Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03795298 · ClinicalTrials.gov registry record · NA
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 1,600
- Enrollment target
NCT03795298: Completed NA study, sponsored by Boston Scientific Corporation.
NCT03795298 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,600 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03795298, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,600 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.
Primary Outcome
Occurrence of stroke (including ischemic and/or hemorrhagic), all cause death, and systemic embolism events adjudicated by an Independent Clinical Event Committee
Interventions
- DEVICE WATCHMAN FLX Implant
- DRUG Market-approved OAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2024-07-24 |
| Phase | NA |
What the finished NCT03795298 record still lists
NCT03795298 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which WATCHMAN FLX Implant is the first listed.
NCT03795298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03795298 about?
NCT03795298 is a clinical study titled "Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation". The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.
What is the current status of trial NCT03795298?
This trial is currently completed. It is a NA study. The enrollment target is 1,600 participants. The study started on 2019-05-20. Estimated completion is 2024-07-24.
What interventions are being tested in trial NCT03795298?
The interventions under investigation include: WATCHMAN FLX Implant (DEVICE), Market-approved OAC (DRUG).
Who is sponsoring clinical trial NCT03795298?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03795298's enrollment target sits among peer trials
1,600 63rd of 2000 higher than 1,937 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI